GGrantIndex
← Leaderboards

Carol E Green

Sri International

Google Scholar ↗PubMed ↗ORCID ↗
$19,982,282
Attributed
$20,172,690
Total exposure
12
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5M · FY2005–24
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$20,172,690 · 12

By mechanism

N01$18,280,996 · 9
R33$1,606,082 · 2
R43$285,612 · 1

Top collaborators

Most similar at Sri International

Same institution · by research overlap

Others in their field

Top investigators on “Contracts”

Research focus

ContractsProgramsDesignPharmaceutical PreparationsUnited States National Institutes Of HealthDrug KineticsContractorUnited States Food And Drug AdministrationResourcesPre-ClinicalServicesPreclinical StudyChemistryEquipmentToxicologyTranslational ResearchNational Institute Of Diabetes And Digestive And Kidney DiseasesFormulationSmall MoleculeDoseNeurodegenerative DisordersNovel TherapeuticsDiabetes MellitusScreening

Grant awards (53)

IGF::OT::IGF TASK ORDER #001 PERFORMANCE AREA 1 MANAGEMENT AND OPERATIONS SUPPORT$82,132
N01 · FY2024 · DA · contact PI
IGF::OT::IGF TASK ORDER #001 PERFORMANCE AREA 1 MANAGEMENT AND OPERATIONS SUPPORT$81,463
N01 · FY2023 · DA · contact PI
NON-CLINICAL SAFETY ASSESSMENT OF ORC-13661 TO SUPPORT AMINOGLYCOSIDE INDUCED HEARING LOSS INDICATION. ADDITIONAL FUNDS.$65,740
N01 · FY2023 · DA · contact PI
IGF::OT::IGF Task Order #3, "Continuous Rodent and Non-Rodent Pharmacokinetic Assessments"$249,645
N01 · FY2022 · DA · contact PI
IGF::OT::IGF TASK ORDER #001 PERFORMANCE AREA 1 MANAGEMENT AND OPERATIONS SUPPORT$80,815
N01 · FY2022 · DA · contact PI
IGF::OT::IGF Task Order #3, "Continuous Rodent and Non-Rodent Pharmacokinetic Assessments"$362,516
N01 · FY2021 · DA · contact PI
IGF::OT::IGF TASK ORDER #001 PERFORMANCE AREA 1 MANAGEMENT AND OPERATIONS SUPPORT$80,197
N01 · FY2021 · DA · contact PI
IGF::OT::IGF Task Order #3, "Continuous Rodent and Non-Rodent Pharmacokinetic Assessments"$749,854
N01 · FY2020 · DA · contact PI
IGF::OT::IGF TASK ORDER #001 PERFORMANCE AREA 1 MANAGEMENT AND OPERATIONS SUPPORT$79,586
N01 · FY2020 · OD · contact PI
IGF::OT::IGF Task Order #3, "Continuous Rodent and Non-Rodent Pharmacokinetic Assessments"$865,846
N01 · FY2019 · DA · contact PI
IGF::OT::IGF TASK ORDER #001 PERFORMANCE AREA 1 MANAGEMENT AND OPERATIONS SUPPORT$78,993
N01 · FY2019 · DA · contact PI
Countermeasures Against Chemical Threats ^ Preclinical Development Facility$99,997
N01 · FY2018 · NS · contact PI
IGF::OT::IGF TASK ORDER #001 PERFORMANCE AREA 1 MANAGEMENT AND OPERATIONS SUPPORT$78,416
N01 · FY2018 · DA · contact PI
Countermeasures Against Chemical Threats ^ Preclinical Development Facility$775,484
N01 · FY2017 · NS · contact PI
IGF::OT::IGF Task Order #3, "Continuous Rodent and Non-Rodent Pharmacokinetic Assessments"$218,286
N01 · FY2017 · DA · contact PI
IGF::OT::IGF DOG DOSE RANGE FINDING (DRF) TOXICITY STUDY - BUCKPITT- LDT-EC5026$179,557
N01 · FY2017 · DA · contact PI
IGF::OT::IGF "Follow-On 28 Day Dog Pharmacokinetic and Clinical Chemistry Assessments"- SRI International$142,909
N01 · FY2017 · DA · contact PI
IGF::OT::IGF TASK ORDER #001 PERFORMANCE AREA 1 MANAGEMENT AND OPERATIONS SUPPORT$77,941
N01 · FY2017 · DA · contact PI
Countermeasures Against Chemical Threats ^ Preclinical Development Facility$917,058
N01 · FY2016 · NS · contact PI
IGF::OT::IGF TASK ORDER #001 PERFORMANCE AREA 1 MANAGEMENT AND OPERATIONS SUPPORT$95,436
N01 · FY2016 · DA · contact PI
THE SYNTHESIS AND PRECLINICAL STUDIES OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASES$5,962
N01 · FY2016 · AG · contact PI
Countermeasures Against Chemical Threats ^ Preclinical Development Facility$1,093,306
N01 · FY2015 · NS · contact PI
Rodent Pharmacokinetic and Brain Level Determination$196,987
N01 · FY2015 · MH · contact PI
IGF::OT::IGF GLP Services to Support IND for Alzheimer's Candidate Drugs$712,207
N01 · FY2014 · DA · contact PI
THE SYNTHESIS AND PRECLINICAL STUDIES OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASES$437,862
N01 · FY2014 · AG · contact PI
IGF::OT::IGF: Non-GLP Services to Support an IND for Azheimer's Candidate Drugs$399,368
N01 · FY2014 · DA · contact PI
THE SYNTHESIS AND PRECLINICAL STUDIES OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASES$122,060
N01 · FY2014 · AG · contact PI
IGF::OT::IGF Administrative Task, Year 4, CAN No. 8478279 Pharmacology and Toxicology for Neurotherapeutlcs Program$104,214
N01 · FY2014 · MH · contact PI
THE SYNTHESIS AND PRECLINICAL STUDIES OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASES$100,608
N01 · FY2014 · AG · contact PI
THE SYNTHESIS AND PRECLINICAL STUDIES OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASES$91,949
N01 · FY2014 · AG · contact PI
THE SYNTHESIS AND PRECLINICAL STUDIES OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASES$88,642
N01 · FY2014 · AG · contact PI
THE SYNTHESIS AND PRECLINICAL STUDIES OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASES$70,043
N01 · FY2014 · AG · contact PI
Investigational New Drug Toxicology for Drugs to Treat Alzheimer's Disease and Ot$60,187
N01 · FY2014 · AG · contact PI
IGF::OT::IGF: General Contract Consultation and Logistics.$43,474
N01 · FY2014 · DA · contact PI
THE SYNTHESIS AND PRECLINICAL STUDIES OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASES$29,053
N01 · FY2014 · AG · contact PI
THE SYNTHESIS AND PRECLINICAL STUDIES OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASES$16,783
N01 · FY2014 · AG · contact PI
Investigational New Drug Toxicology for Drugs to Treat Alzheimer's Disease and Ot$1,462
N01 · FY2014 · AG · contact PI
The Synthesis and Preclinical Studies of New Treatments for Neurodegenerative Dis$859,654
N01 · FY2011 · AG · contact PI
Pre-clinical development of PPCM Vaginal Microbicide$285,612
R43 · FY2011 · AI
The Synthesis and Preclinical Studies of New Treatments for Neurodegenerative Dis$200,009
N01 · FY2011 · AG · contact PI
Pharmacology and Toxicology for Neurotherapeutics Program (PTNP)$155,434
N01 · FY2011 · MH · contact PI
Preclinical Pharmacological Studies of Antitumor and Other Therapeutic Agents$57,300
N01 · FY2011 · CA · contact PI
Preclinical Pharmacological Studies of Antitumor and Other Therapeutic Agents$3,100,000
N01 · FY2010 · CA · contact PI
Countermeasures Against Chemical Threats ^ Preclinical Development Facility$1,810,576
N01 · FY2010 · NS · contact PI
Preclinical Pharmacological Studies of Antitumor and Other Therapeutic Agents$70,000
N01 · FY2010 · CA · contact PI
Countermeasures Against Chemical Threats ^ Preclinical Development Facility$2,456,015
N01 · FY2009 · NS · contact PI
Preclinical Pharmacological Studies of Antitumor and Other Therapeutic Agents$93,514
N01 · FY2009 · CA · contact PI
Systems to Predict Drug-induced Pulmonary Toxicity$684,396
R33 · FY2005 · CA
In Vitro Systems to Predict Hepatobiliary Toxicity$313,187
R33 · FY2005 · CA
In Vitro Systems to Predict Hepatobiliary Toxicity$608,499
R33 · FY2004 · CA
CHEMICAL DISPOSITION IN MAMMALS SRI INTERNATIONAL$542,456
N01 · FY2000 · ES
PHARMACOKINETIC &TISSUE DISTRIBUTION OF H3-EGCG$0
N01 · FY2000 · CN
CHEMICAL DISPOSITION IN MAMMALS SRI INTERNATIONAL$0
N01 · FY2000 · ES